 |
|
|
| |
The Nonsteroidal Farnesoid X Receptor Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis:
A Phase 2, Randomized, Placebo-Controlled Trial
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Michael Trauner,1 Aliya Gulamhusein,2 Bilal Hameed,3 Stephen Caldwell,4 Mitchell L. Shiffman,5
Charles Landis,6 Bertus Eksteen,7 Kosh Agarwal,8 Andrew Muir,9 Simon Rushbrook,10 Tuan Nguyen,11
Xiaomin Lu,11 Georgia Li,11 Chuhan Chung,11 G. Mani Subramanian,11 Robert P. Myers,11
Christopher L. Bowlus,12 Kris Kowdley13
1Medical University of Vienna, Vienna, Austria; 2University of Toronto, Toronto, ON, Canada; 3University of California, San
Francisco School of Medicine, San Francisco, CA, USA;4University of Virginia, Charlottesville, VA, USA; 5Bon Secours Liver Institute,
Richmond, VA, USA; 6University of Washington School of Medicine, Seattle, WA, USA; 7Aspen Woods Clinic, Calgary, AB, Canada;
8King's College, London, UK; 9Duke University School of Medicine, Durham, NC, USA;10Norfolk and Norwich University Hospital,
Norfolk, UK; 11Gilead Sciences, Inc., Foster City, CA, USA; 12University of California Davis, Davis, CA, USA; 13Swedish Organ
Transplant and Liver Center, Seattle, WA, USA
|
| |
|
|
|
|
|
